Madrigal Pharmaceuticals Inc

MDGL has formed a Stage 2 accumulation base, consolidating in a tight range above rising EMAs. Medium-term bias is bullish, favoring long entries on breakouts or high-conviction pullbacks. Short-term execution is on hold as price is extended above EMAs and near overbought conditions, warranting patience. Long-term trend remains intact above the 200 DMA.

• ↑Q2 revenue rose 71% YoY to $364.3M, driven by ResDifera demand.
• ↑ResDifera prescribed to over 49,000 patients, signaling robust market penetration.
• ↓Q2 net loss of $57.9M reflects SG&A expenses of $289.4M.